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Abstract: 
 
Glucocorticosteroids (GCs) are routinely administered systemically or injected into the eye 
when treating numerous ocular diseases, however their toxicity on the retinal 
microvasculature has not been previously investigated. In this paper, the effects of 
Hydrocortisone (Hydro), Dexamethasone, Dexamethasone-Phosphate and Triamcinolone 
Acetonide (TA) were evaluated on the microcirculation of human skin, bovine retinal cells 
and, ex-vivo, on flat mounted rat retinas. 
The degree of GCs induced endothelial cell death varied according to the endothelial cell type 
and GCs chemical properties. GCs toxicity was higher in skin microvascular endothelial cells 
and for hydrophobic GC formulations. The mechanism of cell death differed between GCs, 
Hydro and TA activated the Leukocyte Elastase Inhibitor/L-DNase II pathways but did not 
activate caspases.The mechanisms of cell death observed in cell cultures were similar to those 
observed in rat retinal explants. Taken together these results indicate that a particular attention 
should be paid to the potential vascular side effects when administrating GCs clinically and in 
particular when developing sustained-release intraocular devices. 
 
Keywords: Glucocorticoids, endothelial cell, retinal microvasculature, apoptosis, dermic 
endothelial cell. 
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Introduction 
Glucocorticoids hormones easily cross cell membranes due to their lipophilicity and exert 
physiological effects in almost every tissue of the human body (Cockrem 2013, Walker, et al. 
2012). Synthetic or semi-synthetic glucocorticoids (GCs) aim to optimize the 
immunosuppressive, angiostatic and anti-inflammatory properties of cortisol, whilst reducing 
their mineralocorticoid side effects. GCs remain the first-line therapy in number of 
inflammatory conditions and are administered locally or systemically (Barnes 2005, Logie, et 
al. 2010). Recognized side effects of GCs include microvascular fragility, atrophy as well as 
reduced microvascular density in skin, bone and muscle (Anacker, et al. 2011, Schacke, et al. 
2002, Torriglia, et al. 2010). 
Folkman et al. demonstrated that Hydrocortisone (Hydro) and Dexamethasone (Dexa), at 
µg/µl concentrations, prevent heparin-stimulated angiogenesis in the chick chorioallantoic 
membrane and induce the regression of capillaries within the surrounding tissue (Folkman 
and Ingber 1987, Folkman, et al. 1983). Later, Small et al. showed that corticosterone (300–
600nM) inhibits angiogenesis in vitro and in vivo. In addition, inhibition of 11beta-
hydroxysteroid dehydrogenase type 1 favors corticosterone production and enhances 
angiogenesis providing evidence for the angiostatic role of endogenous corticosteroids (Small, 
et al. 2005). More recently, the mechanisms of the angiostatic effects of physiological doses 
of the endogenous corticosterone have been studied in more details, revealing a receptor-
mediated effect on Vascular Endothelial Growth Factor production, activation of Matrix 
Metallo peptidase 2 and the inhibition of endothelial cells tube-like structure formation 
(Shikatani, et al. 2012). Systemic administration of GCs triggered cell death of macrophages 
(Schmidt et al., 1999), human epithelial cells of the lens (Sharma, et al. 2011), pericytes 
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(Katychev, et al. 2003) and induced necrosis of microvessels and osteocytes in the co-femoral 
articulation and bruises (Allen, et al. 2003, Hu, et al. 2006). 
The possibility that higher doses of corticosteroids may exert further direct effects on an 
established microvasculature has not been extensively explored.  
In ophthalmology, GCs are commonly used not only for the treatment of ocular inflammation 
but also to manage macular edema of inflammatory and non-inflammatory origins such as 
diabetic retinopathy or retinal vein occlusion. As chronic use is required, high doses of the 
hydrophobic Triamcinolone Acetonide (TA) or polymeric implants releasing Dexa for 
sustained periods are used in order to reduce the frequency of intraocular administrations 
(Behar-Cohen 2011). In addition, ocular tissues are resistant to the use of GCs due to the high 
concentration of natural steroid (Knisely, et al. 1994), explaining the high concentrations 
(about 1mg/ml) used clinically. GCs exert rapid and striking effects on retinal edema 
(Miyamoto, et al. 2006) but are associated with potential side effects on the posterior segment 
of the eye including a reduction of the choroidal vascular network,  a decreased retinal vessels 
diameter in rats and a decrease in the retinal vascular density in the developing retinal 
vasculature (Hartnett, et al. 2006, Valamanesh, et al. 2009). Whether GCs can directly affect 
endothelial cell viability has not been fully explored. 
On the one hand, as compared to bone, muscle or skin where vasculature is constantly 
remodeled, retinal endothelial cells proliferate at a very slow rate in normal conditions 
(Joussen, et al. 2007). On the other hand, GCs failed to demonstrate anti-angiogenic effects in 
retinal or choroidal neovascularisation (Chan, et al. 2011, Geltzer, et al. 2013) suggesting that 
GCs may exert different effects on endothelial cells from different tissue origin. We have 
previously shown that clinical doses of intraocular TA induced a caspase independent 
apoptosis associated with the absence of TUNEL labeling on bovine retinal endothelial cells 
in culture and in retinal neovessels (Torriglia, et al. 2010, Valamanesh, et al. 2009). This 
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suggested that non classical mechanism of cell death like autophagy, caspase independent 
apoptosis or necrosis (Galluzzi, et al. 2012) could be involved in this toxicity. 
Taken together, all these results suggest that the molecular mechanisms underlying GCs 
effects on the vasculature are complex and involve different cellular and molecular pathways 
depending on the endothelial cell type, the GC concentration and duration of exposure.  
The aim of this study was to compare the potential toxicity of commonly used GCs (Le 
Jeunne 2012) on vascular endothelial cells of different origin and to investigate the underlying 
mechanisms of toxicity for the different GCs. This is a very important point since the 
evaluation of toxicity relays frequently in caspase-dependent markers and could be 
underestimated if other molecular mechanisms are involved. The relevance of our in vitro 
findings was assessed by analyzing GCs effects on rat retinal explants.  
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MATERIALS AND METHODS 
Animals 
Adult males Lewis rats (6-8 weeks old, Janvier, Le Genest-Saint-Isle, France) were used for 
the ex-vivo experiments. Rats were sacrificed by carbon dioxide inhalation. All experiments 
were performed in accordance with the European Communities Council Directive 
86/609/EEC and approved by the local ethical committee of University Paris Descartes.  
HMEC Culture 
All culture media and additives were purchased from Invitrogen (Cergy Pontoise, France). All 
glucocorticoids (GCs) were purchased from Sigma-Aldrich (Saint-Quentin Fallavier France). 
Human dermal microvascular endothelial cells (HMEC) is a transformed cell line which has 
been transfected with a PBR-322 plasmid containing a region encoding for the SV40 (Simian 
Virus) gene (Ades, et al. 1992). Cultures were maintained at 37°C in a humidified atmosphere 
containing 5% CO2. They were cultured in the Endothelial Basal Medium supplemented with 
L-Glutamine and Hepes 15 mM, 10 % complement-free Fetal Calf serum (DFCS) and 1% 
streptomycin (100 µg/ml) – penicillin (100 units/ml). Confluent HMEC cells were treated 
with the LC50 of GCs: 275 µM Hydrocortisone (Hydro), 255 µM Dexamethasone (Dexa), 230 
µM Triamcinolone Acetonide (TA) and 2 mM Dexamethasone-Phosphate (Dexa-Ph) in media 
supplemented with 2% of DFCS for 24 h. Although cell survival reaches a plateau with Dexa-
Ph, 2 mM was the concentration giving the most reproducible results. The hydrophobic GCs 
(all except for Dexa-Ph) were previously dissolved in ethanol 100% then in the medium 
(ethanol final concentration 1%). This step was introduced in order to have a known 
concentration of the GCs in the media of treatment. Actually, hydrophobic GCs as TA, for 
instance, precipitate in aqueous medium. This false the real concentration of the GC and 
generates crystals that precipitate, stick to cells and cause a mechanical damage. 
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BREC Culture 
Bovine Retinal Endothelial cells (BRECs) were isolated from the Bovine retinal 
microcirculation as previously reported (Capetandes and Gerritsen 1990). BREC were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with GlutaMAX, 4.5 g /L 
Glucose, 10% decomplemented fetal calf serum (DFCS), 1% streptomycin (100 µg/ml) – (100 
Unites/ml) penicillin, 0.5% Fungizone-Amphotericine and 20 ng/ml FGFb. Cultures were 
maintained at 37°C in a humidified atmosphere containing 5% CO2. Confluent BRECs cells 
were treated with LC50 GCs 1.37 mM for Hydro, 765 µM Dexa, 460 µM TA and 2 mM for 
Dexa-Ph in media supplemented with 2% DFCS for 24 h. The hydrophobic GCs (all except 
for Dexa-Ph) were previously dissolved in ethanol 100% then in the medium (ethanol final 
concentration 1%). The choice of this cell line was forced by the difficulty of obtaining an 
equivalent from human origin. 
Rat Retinal Explants 
After enucleation, rat retinas were isolated immediately under aseptic conditions. They were 
flattened by 4 orthogonal incisions, then transferred onto a Cyclopore 0.2 µm polycarbonate 
membrane (Whatman, Maidstone, England), and mounted with the vitreal side up. The 
support membranes were placed in 6-well tissue culture plates containing 2 ml DMEM 
supplemented with 10% steroid-free FCS, 1% penicillin-streptomycin and 0.1% 
Amphotericin-B. Explants were treated with LC50 of BREC cells as described for BREC 
cultured cells.  
MTT ASSAY 
The MTT assay is a colorimetric test that was developed to determine the survival and growth 
of eucaryotic cells in proliferation or to evaluate cytotoxicity (Mosmann 1983).The ability to 
reduce the Tetrazolium salts by HMEC and BREC cells was used to evaluate the toxicity and 
LC50 of GCs. Briefly, cells were seeded in 24-multiwell plates at a density of 5x10
4
cells in 
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1ml of complete medium. Confluent cells were treated during 24 h with increasing 
concentrations of CGs. At the end of the treatment, 250 µl of CellTiter 96 Non-Radioactive 
Cell Proliferation Assay (MTT; Promega, G4000) (5 mg of MTT per ml of phosphate-
buffered saline) were added to each well, including six wells that contained only medium or 
medium containing 1% ethanol (controls). Plates were then incubated for 1 h at 37°C in the 
dark and analyzed with a microplate reader (BioRad Benchmark, Paris, France) at 570 vs 630 
nm. Experiments were performed in triplicate and repeated three times. 
 
Caspases inhibition 
30 min prior to treatment HMEC cells were incubated in 10µM ZVAD-FMK 
(Benzoyloxycarbonyl-val-ala-asp-fluoromethyl ketone) (ApexBio A1902). Treatment was 
initiated by adding GCs at the CL50 concentrations in the same medium. Controls included 
0.2% DMSO, the vehicle of ZVAD (not shown). Etoposide treatment, 100µM for 24h, was 
used as a positive control of caspase activation. Cell survival was measured by the MMT 
method. 
 
Internucleosomal DNA degradation 
Internucleosomal DNA degradation assay was performed as already described by Zhua et al 
(Ning Zhua 1997). Briefly, cells from each condition were obtained by scraping in culture 
medium. A cell pellet was obtained by centrifugation at 173g, then the pellet was extracted in 
30µl of Sarkozyl (50 mM of Tris,10 mM of EDTA, 2% of N-Lauryl sarcosine at pH 7.5) and 
immediately stored on ice. The cellular lysates were then treated for 2 h with1µl of proteinase 
K 20 mg/ml at 45°C and 1µl of RNase-A 10 mg/ml for 1hr at 37°C. Finally, the DNA 
samples were run in a Tris-Acetate-EDTA 2% agarose gel and visualized by staining with 
ethidium bromide. 
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Lactate dehydrogenase (LDH) assay 
LDH is a cytoplasmic enzyme not released during active cell death like apoptosis, paraptosis, 
or autophagy, but released in necrosis due to the early increase of plasma membrane 
permeabilization. The LDH assay was performed according to the manufacturer’s instructions 
of the LDH Cytotoxicity Detection Kit (Roche Applied Sciences). Following GCs treatment, 
an aliquot of culture supernatant was immediately stored on ice. Cells incubated with 1% 
Triton-X100 represented the positive control (100% of LDH release).The enzymatic reaction 
was initiated by the addition of 100 µl of reaction mixture (provided in the Kit) with 100 µl of 
supernatant during 30 min at room temperature. Reaction products were assessed 
spectrometrically at an absorbance of 490 nm versus 630 nm in 96 multi-well plates. The 
percentage of lysed cells was calculated using the following formula: 100× [(experimental 
LDH release)/(maximum LDH release)]. The maximum of LDH release corresponding to the 
amount of LDH released by a total lysis of the cells with Triton-X100. These experiments 
were performed 4 times. 
 
Indirect Immunofluorescence experiments 
Cells were seeded at density of 5.10
4 
cells in 1 ml of complete medium in Lab-Tek devices (4 
wells, Glass slide). Confluent cells were treated with LC50 of GCs at the indicated 
concentrations according to the cellular origin. The following proteins were tested: Light 
Chain 3 (LC3), cleaved Caspase-3, Apoptosis Inducing Factor (AIF) and Leukocyte Elastase 
Inhibitor/ LEI-derived DNase II (LEI/L-DNase II). At the end of the treatments, cells were 
washed three times with PBS (Phosphate Buffer Saline), fixed with 4% paraformaldehyde for 
15 min at room temperature, washed three times in PBS, permeabilized with 0.3% de Triton-
X100 for 15 min, washed three times with PBS for 5 min and then saturated with 1% BSA 
10 
 
(Bovine Serum Albumin) in PBS for 1 hr. Slides were then incubated with the polyclonal 
antibody against LC3 (Santa Cruz Biotechnology, sc-16756) and monoclonal antibody against 
AIF (EPITOMICS, ab32516) diluted 1:100 in PBS-0.1% BSA, overnight at 4°C, washed five 
times with PBS, incubated with the secondary antibodies: anti goat (Invitrogen, A11055, 
Alexa Fluor®) and anti-rabbit (Invitrogen, A10040, Alexa Fluor®) diluted 1:200 in PBS and 
incubated for 1 h at room temperature in a humidified chamber. Cells were then washed three 
times with PBS in the dark and finally mounted with Fluoromount (Sigma Life Sciences). For 
LEI/L-DNase II cell labeling was performed as described before (Altairac, et al. 2003). For 
cleaved Caspase-3 labeling, after fixation and permeabilization performed as above, cells 
were washed three times with PBS and then saturated with 1% skim milk in PBS for 1 hr. 
Cells were then incubated with monoclonal antibody against active caspase-3 (Cell Signaling, 
9661S) diluted 1:100 in 0.1% skim milk PBS, overnight at 4°C, washed five times for 5 min 
with PBS, incubated with the secondary antibody (Invitrogen, A10040, Alexa Fluor® anti-
rabbit) diluted 1:200 in PBS, for 1 h at room temperature in a humidified chamber. Cells were 
then washed three times with PBS in the dark and finally mounted with Fluoromount (Sigma 
Life Sciences). Cells were observed using a fluorescence microscope Olympus BX51, 
equipped with  40x and 60x objectives. Confocal analysis was done using a Zeiss LMS710 
microscope. Adobe Photoshop was used as elaborating software.  
Cytoplasm and nucleus fractions 
Cells were collected by trypsinization and rinsed twice in PBS, then, 2.10
6
 cells were resumed 
in 500 µl of a hypotonic solution of MgCI2 (1.5 mM) during 10 min. Cells were then crushed 
with a Dounce potter and centrifuged 10 min at 390 g. The cytoplasmic fraction contained in 
the supernatant was removed and the nuclear fraction was resuspended in 1 mL of MgCI2 (1.5 
mM) and centrifuged during 10 min at 390 g twice, then resuspended in 200 µl of 10 mM 
Tris, 60 mM NaCl, 200 mM sucrose pH 7,4. 
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To measure the concentration of proteins in both cellular fractions, 10µl of the cytoplasmic 
and nuclear fractions are mixed to 250 µl of reactive solution (Pierce
®
 BCA Protein Assay 
Kit, 23225) in a 96 multiwells plate. The plate was incubated 30 min at 37°C then the optical 
density was read in BioRad Benchmark plate reader at 595 nm. The obtained measures were 
correlated to a standard curve of BSA made in duplicate (0 to 1200 µg/µl). The sample 
concentration was calculated by linear regression. 
Western blot analysis 
Cells were disrupted in RIPA buffer (50 mM Tris, 150 mM NaCl, 1% Triton-X100, 1% 
Sodium Deoxycholate, 1% Sodium Dodecyl Sulfate) or M-PER buffer (Thermo Scientific, 
78503) in the presence of protease and phosphatase inhibitors. The protein concentration was 
determined by the BCA method (as previously described). The proteins were distorted in 
Laemmli (62 mM Tris-HCI 6.8 pH, 2% SDS, 10% glycerol, 5% ß-mercaptomethanol, 0.01% 
Bromophenol blue). Equal amounts of protein (20 µg) were separated on a 12% Tris-Glycine 
gel. Nitrocellulose membrane transfer was performed at 100 V for 1:30 h at 4°C and 
monitored by the membrane staining with Ponceau Red (Sigma-Aldrich). The membrane was 
saturated with 5% skim milk in PBS for 1 h at room temperature then incubated overnight at 
4°C with the primary antibodies against caspase-3 (1:1000) (Santa Cruz,1224), cleaved 
caspase-3 (1:1000) (Cell Signaling,9661), AIF (1:1000) (Santa Cruz, 9416), LEI/L-DNaseII 
(1:1000) (Torriglia, et al. 1995), β-Actin (1:1000) (Santa Cruz, 1616), Lamin B (1:1000) 
(Santa Cruz, 6216), LC3-II (1:1000) (Santa Cruz sc-16756). After 5 washes in PBS 
containing 0.1% Tween-20, the membrane was incubated for 1 hr with the anti-rabbit (Victor 
Laboratories, PI-1000) or anti-Goat (Victor Laboratories, PI-9500) secondary antibodies 
conjugated to peroxidase, diluted 1:5000, in PBS containing 0.5% Skim Milk and then 
washed 5 times in PBS. PARP (Poly ADP-Ribose Polymerase) western blot was performed as 
already described by Blenn and al (Blenn, et al. 2006). Visualization of the immunoreactive 
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bands was obtained by a chemoluminescent substrate, SuperSignal West Pico 
Chemiluminescent Substrate (Thermo scientific, 34087) using a MicroChemi 4.2 DNR 
BioImaging System. 
 
Retinal flat mounting 
After GCs treatment, retinas were immediately washed and fixed with 4% paraformaldehyde 
for 15 min. They were then permeabilized with PBS containing 0.1% Triton X-100, and 
incubated with the rabbit anti-caspase-3 and mouse anti-von Willebrand antibody or the 
chicken anti-LEI and rabbit anti-von Willebrand (1:100) overnight at 4°C. After washing 5 
times with PBS, retinas were incubated with the secondary antibody (Alexa Fluor® 405-
conjugated goat anti-rabbit IgG and Alexa Fluor® 594-conjugated Donkey anti-mouse IgG or 
Alexa Fluor® 568-conjugated goat anti-chicken IgG and Alexa Fluor® 405-conjugated goat 
anti-rabbit IgG (1:200)) for 1 hr. For phosphatase treatment, retinas were incubated for 30 min 
at 37°C with calf intestinal alkaline phosphatase (CIAP, Invitrogen, 8009-019) in 
dephosphorylation buffer (Invitrogen, P/N 01371) then washed 3 times. The 
dephosphorylation has as objective to unmask 3’OH DNA extremity stemming from 
activation of L-DNase II.  Finally, Retinas were fixed with 4% paraformaldehyde then 
incubated for 1 hr with 80 μl of terminal deoxynucleotidyl transferase dUTP nick end labeling 
assay (TUNEL, Roche Diagnostics, Mannheim, Germany) reaction mixture at 37 °C. The 
retinas were flat mounted using Fluomount. Images were taken using a confocal laser 
scanning microscope Zeiss LSM 710 (Oberkochen, Germany). 
Statistics 
Data were expressed as means ± SE. Statistical analysis was made using the Graphpad Prism5 
program (Graphpad Software, San Diego, CA, USA). Mann-Whitney test comparison was 
used. P < 0.05 deemed significant, unless otherwise stated. 
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Results  
 Dose-dependent effect of glucocorticoids (GCs) on microvascular endothelial cells 
viability (HMEC, BREC) and lethal concentrations (LC50) determination: 
In order to evaluate the sensitivity of HMEC and BREC to corticosteroids, cells were treated 
with different concentration of Hydrocortisone (Hydro), Triamcinolone Acetonide (TA), 
Dexamethasone (Dexa) and Dexamethasone Phosphate (Dexa-Ph) for 24h. Because 
hydrophobic glucocorticoids (Hydro, TA, Dexa) form dense and adherent toxic aggregates 
when directly added to culture medium (Szurman, et al. 2007), they were first dissolved in 
Ethanol 100%, then in the culture medium. This gave a final concentration of 1% ethanol in 
the medium. The reduced viability measured by the MTT assay was correlated to a reduced 
number of living cells, as verified by the trypan blue assay (not shown).Fig 1 shows that GCs 
had different concentration–dependent reduction of cell viability, depending on the GC and 
the cell type. Dexa-Ph was the less toxic and HMEC were more sensitive than BREC cells.  
 
The mechanisms of cell death induced by GCs: 
In order to analyze the mechanisms underlying GC toxicity on endothelial cells, we 
successively evaluated markers for autophagy, necrosis, caspase-dependent and caspase-
independent apoptosis. These analyses were performed on HMEC using for each steroid its 
LC50 as determined above in order to have results obtained with the same degree of toxicity. 
Autophagy  
The presence of autophagy was analyzed using an antibody against MAP-LC3 (microtubule-
associated protein 1 light chain 3). This protein is integrated to the autophagosomes 
membranes (Tanida, et al. 2004). In physiological conditions, the quiescent LC3 has a diffuse 
distribution in the cytoplasm. Once the autophagy activated, LC3 concentrates in the 
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autophagosome membrane and gives a punctuate labeling as observed in cells cultured in a 
depleted amino-acid (AA) medium, used as a positive control (Fig 2A). No such labeling was 
observed with GCs treatment eliminating autophagy as a potential mechanism of cell death 
(Fig 2A). This result was confirmed by western blot. As seen in Fig 2B only in AA depleted 
medium the lipidated form of LC3 (LC3 II) appeared. 
 
DNA damage and necrosis 
The DNA fragmentation into oligonucleosomal fragments is a widely recognized hallmark of 
apoptotic cell death, as induced by HMA (5-N, N-hexamethylene-amiloride) (used as a 
positive control). The “DNA ladder” pattern was clearly seen in samples treated with Dexa 
and Dexa-Ph, faintly with TA treatment and not at all in Hydro treated cells (Fig 2C). 
Moreover, as some smear degradation is also seen we investigated if necrosis was involved. 
This was done by measuring the release of LDH in the culture medium. A total lysis of the 
cells induced by 1% Triton-X100 was used as a positive control. Amongst the GCs tested at 
their respective LC50 concentrations, only Dexa (255 µM) induced a significant increase of 
LDH release (31.17%; **P≤0.01) as compared to the positive control (Fig 2D).  
 
Caspase-dependent apoptosis in GCs toxicity 
Caspase-3 activation was analyzed by immunocytochemistry (Fig 3A) and western blot (Fig 
3B). Amongst the GCs tested at their respective LC50 concentrations, only Dexa and Dexa-Ph 
induced activation of caspase 3 as observed on immunocytochemistry (Fig 3A). This was 
confirmed by western blot (Fig 3B). Only Dexa and Dexa-Ph induced the cleavage of pro-
caspase 3. Moreover, PARP-1, one of the main targets of activated Caspase-3 was cleaved in 
cells treated with Dexa and Dexa-Ph but not in cells treated with other CGs (Fig 3B). In all 
these experiments the treatment of cells with etoposide, an inhibitor of toposiomerase II, 
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knowing to induce caspase dependent cell death was used as a positive control. The 
involvement of caspases in cell death was evaluated using the pancaspase inhibitor ZVAD-
FMK. Results are seen on Fig 3C. The inhibitor successfully inhibits cell death in etoposide 
but not in GCs treated cells, suggesting that this pathway is not the main effector in GCs cells 
demise. 
 
Caspase-independent apoptosis in GCs toxicity 
Due to the lack of caspase activation in TA and Hydro, as well as the lack of protection with 
pancaspase inhibitor,  we analyzed caspase independent pathways, namely Leukocyte Elastase 
Inhibitor (LEI/L-DNase II) and Apoptosis Inducing Factor (AIF). 
LEI (Leukocyte Elastase Inhibitor) is a cytoplasmic molecule owning an anti-protease 
activity. After induction of apoptosis it is cleaved and transformed into L-DNase II, a 
molecule that has an endonuclease activity and that is translocated to the nucleus (Padron-
Barthe, et al. 2007). 
The activation of L-DNase II was estimated by immunostaining and Western blot. L-DNase II 
activation and nuclear translocation were observed with all GCs (Fig 4A). In order to verify 
the nuclear translocation of this protein we fractionated cytoplasms from nuclei, and 
performed a western blot on both fractions (Fig 4B). We observed the presence of native LEI 
(42 KDa) in the cytoplasmic fractions while the nuclear fractions contained, in addition, one 
band of 35kDa corresponding to the active L-DNase II (Belmokhtar, et al. 2000).Taken 
together these results indicate that GCs activate the LEI/L-DNase II pathway. HMA treated 
cells were used as positive control of L-DNase II activation. 
Concerning AIF, (Fig 5) HMEC cells treated with the GCs presented a cytoplasmic dotted 
labeling which was compatible with its classical mitochondrial localization. 
This localization did not seem modified with the GCs (Fig 5A). Observe that staurosporine 
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treated cells used as positive control of AIF activation showed a diffuse cytoplasmic labeling 
and a nuclear peripheral labeling. As previously done, we verified this result by western blot 
(Fig 5B) after nuclear-cytoplasmic fractionation. The activated, cleaved form of AIF is only 
seen in staurosporine treated cells. These results indicate that the AIF is not activated by GCs 
in HMEC cells. 
 
Effect of glucocorticoids on BREC 
To verify if the cellular phenomena induced by the GCs on the HMEC were reproducible on 
retinal endothelial cells, we analyzed the activation of the cell death pathways previously 
studied.   
For this purpose, BREC were treated for 24 h with LC50, ,then the activation of Caspase-3, 
LEI/L-DNase II and AIF were estimated by immunostaining with the corresponding antibody. 
The activation of Caspase-3 was observed on BREC treated with Dexa and Dexa-Ph, as 
already indicated for HMEC. Hydro and TA did not induce the caspase dependent cell death 
(Fig 6C). In same way, the activation of the LEI and nuclear translocation of L-DNase II were 
observed with all GCs on BREC (As showed in higher magnifications) (Fig 6A).The analysis 
of the immunocytochemistry of AIF on BREC showed a cytoplasmic dotted labeling 
indicating the mitochondrial localization of AIF with all GCs treatment, while cells treated 
with the staurosporine (positive control) revealed a diffuse labeling in the cytoplasm and a 
nuclear translocation (Fig 6B). 
 
Impact of GCs on the retinal microvasculature  
The in vitro experiments described above showed the toxic effects of GCs on HMEC and 
BREC. In order to be closer to physiological conditions, where the endothelial cells are 
organized as microvascular networks, rat retina explants were treated with GCs for 24 h at the 
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LC50 determined for BREC cells. An “ex vivo” model was preferred to a “in vivo” approach in 
order to better control the concentration of GCs reaching the retinal vascular bed. Actually, 
the intravitreal administration of drugs in rodents, due to the size of lens, which is relatively 
big, causes an inhomogeneous distribution of the injected substance and an uneven 
concentration on the different parts of the retina. The retinal microvasculature was 
immunostained with anti-Von Willebrand antibody. The double immunolabeling anti-caspase 
with TUNEL assay or anti-LEI/L-DNase II with TUNEL+Phosphatase assay allowed us to 
analyze the activation of these cell death pathways. As for HMEC and BREC, LEI/L-DNase 
II was activated on retina microvascular cells with all tested GCs as observed in our in vitro 
experiments (Fig 7A). The activation of Caspase-3 was observed in Dexa and Dexa-Ph 
treatments, while Hydro and TA did not induce a caspase-dependent cell death (Fig 7B).  
 
 
Discussion 
Intraocular glucocorticoids (GCs) are widely used to treat retinal diseases, directly injected 
into the vitreous as a non-soluble crystal suspension (like Triamcinolone Acetonide (TA)) or 
more recently as polymeric poly-lactic-co-glycolic acid (PLGA) implants releasing 
Dexamethasone (Dexa). The choice of the glucocorticoid is empirical since very few studies 
have compared their potential toxic and beneficial effects. In this study, we have focused on 
the potential toxicity of GCs on the microvasculature. We have focused on established 
microvasculature rather than in neovascularization which was largely featured in previous 
studies. Of course, no cellular model recapitulate a clinical condition or an established tissue 
and extrapolation should be performed with caution. In our experiments, we have used 
confluent cells, so that our experimental conditions are closer to established vessels than to 
proliferating vessels. In retinal explants, we have evaluated resting vessels instead of choosing 
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a model of neovascularization. In this study we have compared two cell lines of dermal and 
retinal origin in order to investigate differences in toxicity and we have then evaluated in 
detail the mechanisms of different GCs toxicity.. Our results show that endothelial cells 
originating from the retina (BREC) are less sensitive to all the GCs tested than endothelial 
cells from dermal origin (HMEC). Although the cells are from different origins in terms of 
species and the cells have different culture conditions, various factors concerning the tissue 
origin of the cells could explain this difference.. The first factor could be the natural 
microenvironment of these cells. In the eye, cortisol levels are higher than in the circulation 
and the corticoid-binding globulin is absent, explaining in part the immunologic privilege of 
the intraocular media (Denniston, et al. 2011). Moreover, in inflammatory conditions, as 
shown in experimental model of uveitis, cortisol levels increase in the ocular media 
(Bousquet, et al. 2012). This permanent exposure to high cortisol levels associated with the 
low proliferating capacity of retinal endothelial cells may explain their higher resistance to 
GCs-induced cell death (Joussen, et al. 2007). 
Although the tested drugs belong to the same pharmacological family, they show different 
cellular toxicity. Their differential effects could be related to their relative affinity for gluco or 
mineralocorticoid receptors. Indeed, GCs can exert beneficial or deleterious effects on 
vascular permeability through junction adhesion and cytoskeleton remodeling (Chen, et al. 
2002). However, the concentration of GCs used here is largely over the binding constant for 
these receptors (in the µM range) suggesting that the toxic effects are receptor independent. 
Concerning endothelial cell toxicity, our results show that the more hydrophilic GCs, namely, 
Dexamethasone phosphate (Dexa-Ph) is the less toxic than the more lipophilic, Hydro, Dexa, 
and TA. This difference may be explained, by hydrophilic GCs transferring less easily through 
the intact membranes, resulting in lower bioavailability in cells and thus less toxic. It is worth 
noting that the toxicity measured here is not related to the anti-inflammatory activity of these 
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compounds. Compared to Hydro, TA has 5 to10 fold greater anti-inflammatory activity, while 
Dexa has 20 to 40 fold greater activity. However, their LC50 are quite similar (255 µM for 
Dexa, 230 µM for TA)(Cohen and Jacquot 1981, Le Jeunne 2012). 
TA is the most widely administered intraocular GC and is usually given in a formulation not 
specifically adapted to ophthalmological use, as it was originally designed for intramuscular 
and intra-articular administration. Studies on the toxicity of TA and/or its excipient 
(benzyliquealcohol), the crystalline or soluble formulations, led conflicting rather than 
conclusive results (Torriglia, et al. 2010, Valamanesh, et al. 2007). Indeed, toxicity of TA and 
its excipient was not found in certain studies (McCuen BW 2nd 1981, Narayanan, et al. 2006) 
while other works clearly established the toxicity of TA and/or the excipient in the eye, 
resulting in a disorganization of the retina layers, a loss of the choroid network density and a 
vasoconstriction of the retina blood vessels (Morrison, et al. 2006, Torriglia, et al. 2010, 
Valamanesh, et al. 2009). 
TA showed concentration and time dependent cytotoxicity on retinal pigment epithelium cells, 
glial cells and endothelial cells of the retina. This toxicity triggered a reduction in 
mitochondrial activity, and an activation of caspase-independent cell death mechanism 
(paraptosis in EPR cells, LEI-L-DNase II and AIF in retinal endothelial cells (Narayanan, et 
al. 2006), (Valamanesh, et al. 2007, Yeung, et al. 2003)). This may explain the results 
obtained by some authors that showed no caspase activation after 24 h of treatment with TA 
on primary human retinal microvascular and flat mounted rat retinas (Hartnett, et al. 2006). 
Hence, the assessment of cell death pathways is an essential step in estimating the safety or 
the toxicity of health products. We show here that different cell death mechanisms other that 
classical caspase dependent apoptosis are responsible for cell death induced by GCs and that 
the same mechanisms seen in cell culture were also seen ex-vivo (microvessels of retina). 
Moreover, the use of the pancaspase inhibitor, ZVAD on HMEC show a lack of protective 
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activity regarding all the GCs suggesting that caspases are not the main effectors in this cell 
death. 
In this study the toxicity of several GCs was estimated and compared for the first time, on 
microvascular endothelial cells of different tissue origins. This toxicity was previously 
disregarded because the tests used were not suitable for evaluating caspase-independent cell 
death. Strikingly, the concentrations used in our experiments, that proved to be cytotoxic, 
were lower than those used clinically. For instance, 4 mg of TA are injected in the human 
vitreous to treat macular edema. This produces a concentration of 1mg/ml (approximately 2.3 
mM) of TA in the vitreous (lasting up to 1 month) due to the slow clearance of drugs in this 
compartment. The vitreous humor levels measured by several authors after triamcinolone 
acetonide intravitreous injection, are higher than the LC50 found in both HMEC and BREC 
(around 4 mM as compared to 230 and 460 µM for HMEC and BREC respectively) (Oliveira, 
et al. 2012).   
GCs have widespread clinical applications in the eye and in other organs and their use is often 
the only available therapeutic option.  In this work we demonstrated that high concentrations 
of these compounds could be toxic to endothelial cells, of microvasculature and target tissues. 
It is essential to ensure their concentrations remain under the toxic threshold for endothelial 
cells when developing novel therapeutic protocols. 
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Legends  
Figure 1: Evaluation of the toxicity and lethal dose (LC50) of different glucocorticoids 
(GCs) on human endothelial cells (HMEC) or bovine retinal endothelial cells (BREC). 
Cells were treated with Hydrocortisone (Hydro), Triamcinolone Acetonide (TA), 
Dexamethasone (Dexa), Dexamethasone Phosphate (Dexa-Ph) for 24 h at the indicated 
concentrations. The lipophilic GCs (Hydro, TA, and Dexa) were dissolved in Ethanol 100% 
then in cell culture medium. Control cells were either exposed to 1% ethanol or were left 
untreated. Cell viability was evaluated using the MTT assay. (A) HMEC; (B) BREC The 
lipophilic GCs show a concentration-response relationship between the decline of viability 
and the increase of the dose while Dexa-Ph is less toxic. These are representative results of 
three different experiments. 
 
Figure 2: Cell death in GCs treated HMEC cells. (A) The activation of autophagy process 
was evaluated by anti-LC3 immunocytochemistry. HMEC cells were treated for 24 h with the 
LC50 of GCs. For the positive control cells were incubated with medium lacking amino acids. 
HMEC cells were fixed, permeabilized and immunostained with anti-LC3 (green), all 
treatments revealed diffuse cellular labeling of LC3 confirming the absence of autophagic 
vesicles. Scale bars represent 5µm. (B) Cells treated as above were analyzed by western blot. 
The activation of autophagy in  AA deprived cells triggers the appearance of a 14kDa band, 
LC3II, the lipidated form of LC3. (C) DNA extracted from HMEC treated with LC50 of GCs 
were analyzed by electrophoresis on a 2% agarose gel. Oligonucleosomal fragments of DNA 
are seen with Dexa, Dexa-Ph and slightly with TA. Control: Untreated cells, Ethanol 1%: 
medium containing 1% of ethanol, treatment with 40 µm HMA (5-N, N-hexamethylene-
amiloride) was used as a positive control for apoptosis. (D) The release of lactate 
dehydrogenase (LDH) from HMEC cells treated 24 h with LC50 of GCs was measured in the 
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culture medium and compared to the maximal LDH release, determined by exposing the cells 
to 1% of Triton X-100. Each experiment was performed in triplicate. Data are expressed as 
medium percentage of LDH released into the media. Dexamethasone induced an increased 
release of LDH as compared to control and to the other treatments (**P≤0.01).This is a 
representative experiments out of 4. 
 
Figure 3: The activation of caspases in GCs treated HMEC cells. (A) The activation of 
caspase-3 by immunolabelling of HMEC cells using an anti-active caspase-3 antibody (red). 
Cells were exposed for 24 h with the LC50 of GCs. Cells incubated with Etoposide were used 
as positive control. Only Dexa and Dexa-Ph induced an activation of caspase-3 (arrows). 
These are representative results out of 3 independent experiments. Scale bars represent 7 µm. 
(B) Caspase-3 and PARP western-blot analysis. Protein extracts from GCs treated HMEC 
cells were analyzed in a 12% acrylamide gel, transferred to nitrocellulose and revealed with 
anti-caspase-3. Apoptosis induced in HMECs with Etoposide (100 µM for 24 h) was used as 
positive control. Activated caspase-3 and cleaved PARP were detected in HMECs treated 
with Dexa and Dexa-Ph, showing that both GCs induce caspase-3 activation. Representative 
results of 3 experiments. (C) Effect of ZVAD on HMEC survival. Cells were exposed for 24 h 
with the LC50 of GCs in the presence (grey bars) or in the absence (white bars) of ZVAD-
FMK. Cells incubated with Etoposide were used as positive control.  MTT was used to 
evaluate cell viability. No protective effect is seen in GCs treated cells. Results were analyzed 
by the ANOVA test using the Newman-Keuls post test. *** indicates significant differences 
p< 0.001. 
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Figure 4: Activation of the L-DNase II pathway in GCs treated HMEC cells. (A) HMEC 
cells were treated with the LC50 of GCs for 24 h and immunostained with an anti-LEI/L-
DNase II (red). HMEC Cells exposed to HMA represent the positive control. All the GCs led 
to LEI/L-DNase II activation with an intense nuclear staining. Scale bar represents 10µm. 
These are representative results out of 4 experiments. (B) GCs treated HMEC were 
fractionated into cytoplasmic and nuclear fractions. Western blot analysis using an anti-
LEI/L-DNase II revealed an accumulation of L-DNase II in the nucleus of treated cells, 
phenomena also seen in HMA treated cells used as positive control. 
 
Figure 5: AIF activation in GCs treated HMEC cells. (A) Nuclear translocation of AIF was 
evaluated by anti-AIF immunocytochemistry (green). HMEC cells were treated for 24 h with 
the LC50 of GCs, for the positive control cells were treated with Staurosporine (Stauro). 
Control cells and GCs treated cells revealed a dotted labeling of AIF. Scale bars represent 10 
µm. These are representative images of 2 independent experiments performed in 
quadruplicate (B) AIF western blot was performed on nuclear and cytoplasmic fractions. AIF 
was present in all cytoplasmic fractions, only the Staurosporine treated cells, used as a 
positive control, show a nuclear translocation of the truncated (active) form of AIF. 
Representative experiment out of 2.  
 
Figure 6: The activation of caspase dependent and independent cell death in GCs treated 
BREC cells. For all experiments BREC were treated during 24h with LC50 of GCs. (A) 
BREC cells were immunostained with an anti- LEI / L-DNase II. Cells exposed to HMA 
represent the positive control. All the GCs led to LEI/L-DNase II activation with an intense 
nuclear staining (white arrow heads) the same outcomes was observed previously with 
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HMEC. LEI/L-DNase II was stained in red, nuclei in blue. The right column represents 
confocal images of cells showing a nuclear translocation of L-DNase II. Scale bars represent 
20µm for fluorescence images and 10µm for confocal images. (B) Nuclear translocation of 
AIF in BREC was evaluated by anti-AIF immunocytochemistry. Cells treated with 
Staurosporine represent a positive control. GCs treated cells revealed a dotted labeling of AIF, 
which suggests a mitochondrial localization. White arrow head shows a nuclear translocation 
of AIF. AIF is seen in green, nuclei in blue. Scale bars represent 20µm for fluorescence 
images and 10µm for confocal images.. (C) Activated caspase-3 immunocytochemistry of 
BREC cells. BREC were immunostained with an antibody that specifically recognizes the 
cleaved caspase-3. Etoposide was used as a positive control. Like previously observed with 
HMEC cells only Dexa and Dexa-Ph induced an activation of caspase-3. Activated caspase 3 
is seen in red, nuclei in blue. Scale bars represents 20µm. All experience were performed at 
least 4 times. 
 
Figure 7: Cell death pathway induced by GCs on retinal microvasculature. Retinas from 
Lewis rats were flat mounted, treated with GCs and analyzed. The retinas treated with 
steroids-free medium were used as control. (A) Retinal explants were treated with GCs, and 
immunostained for LEI/L-DNase II (red), TUNEL-Phosohatase (green), and won Willebrand 
factor (blue). L-DNase II was activated with all treatments. (B) Retinal explants were treated 
with GCs, and immunostained for caspase-3 (blue), TUNEL (green) and won Willebrand 
factor (red). The activation of Caspase-3 on retina vessels was induced with Dexa. Scale bar 
represents 30 µm. Each experiment was performed at least 4 times.  
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